nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Antithrombin deficiency: no sugar, no diagnosis!
|
Bianchini, Elsa P. |
|
|
140 |
2 |
p. 83-85 |
artikel |
2 |
Buckling up against COVID-19 after CAR T-cell therapy
|
Auletta, Jeffery J. |
|
|
140 |
2 |
p. 85-87 |
artikel |
3 |
Editorial Board
|
|
|
|
140 |
2 |
p. i |
artikel |
4 |
Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
|
Oh, Bernice Ling Zhi |
|
|
140 |
2 |
p. 156-160 |
artikel |
5 |
GPIIb/IIIa-GPVI–commanded platelet patrol
|
Chatterjee, Madhumita |
|
|
140 |
2 |
p. 81-83 |
artikel |
6 |
Ibrutinib frontline in young patients with CLL
|
Eichhorst, Barbara |
|
|
140 |
2 |
p. 80-81 |
artikel |
7 |
Incorporating signaling dynamics into fate decision
|
Guo, Shangqin |
|
|
140 |
2 |
p. 79-80 |
artikel |
8 |
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
|
Shanafelt, Tait D. |
|
|
140 |
2 |
p. 112-120 |
artikel |
9 |
NfκB signaling dynamics and their target genes differ between mouse blood cell types and induce distinct cell behavior
|
Kull, Tobias |
|
|
140 |
2 |
p. 99-111 |
artikel |
10 |
Procoagulant platelet sentinels prevent inflammatory bleeding through GPIIBIIIA and GPVI
|
Kaiser, Rainer |
|
|
140 |
2 |
p. 121-139 |
artikel |
11 |
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
|
Leebeek, Frank W.G. |
|
|
140 |
2 |
p. 89-98 |
artikel |
12 |
Secondary AML with MLL gene amplification
|
Xu, Ke |
|
|
140 |
2 |
p. 161 |
artikel |
13 |
Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays
|
de la Morena-Barrio, Maria Eugenia |
|
|
140 |
2 |
p. 140-151 |
artikel |
14 |
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
|
Atanackovic, Djordje |
|
|
140 |
2 |
p. 152-156 |
artikel |